When AD is treated with dupilumab, a biological drug that blocks the receptor for IL-4 and inhibits transmission through IL-13, IL-4 activity is inhibited and it cannot inhibit Th17-dependent and IL-17-dependent responses, which are particularly important in the pathogenesis of psoriasis, and can result in the eruption of psoriatic lesions [6]. Here, IL4 is linked to psoriasis.